BioSpace News Archive

Arch Biopartners Inc. announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

MiNK Therapeutics, Inc. today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024.

Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2023.

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma.

Alphyn announced today that the second cohort of its Phase 2a trial evaluating zabalafin hydrogel (AB-101a) in patients with atopic dermatitis (AD) and infected AD skin met all endpoints for safety and efficacy.

3T Biosciences today announced that it has entered into multiple additional collaborations with leading academic centers and principal investigators to further fuel 3T’s best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) pHLA target discovery platform.

Womed, the women’s health company pioneering innovative, safe and effective treatments to free women from uterine pathologies, announced that the results of the PREG2 clinical trial demonstrated Womed Leaf® is effective in the management of severe and moderate intrauterine adhesions, the primary mechanical cause for female infertility.

Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 36th Annual ROTH Conference, taking place March 17-19, 2024.

Clene Inc. today announced that it will participate in the 36th Annual ROTH Conference being held March 18-19, 2024.

Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024.